Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label dose-escalation study of intravenous EXG110 in adults with Fabry disease
CTR20250274Phase 2Active
- Sponsor
- Hangzhou RebornGene Therapeutics Co., Ltd.
- Start
- Jan 2025
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of EXG110 in Fabry disease (FD), sponsored by Hangzhou RebornGene Therapeutics Co., Ltd.. Started Jan 2025; status: active.
02
Drugs
EXG110
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on CTR20250274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250274.